Navigation Links
Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

t indicate treatment-limiting toxicity. The most common adverse event in both treatment groups was upper abdominal pain, which occurred in less than 2% of patients.

Prexige has a different chemical structure from other COX-2 inhibitors. It is the only one that does not contain a sulphur molecule, which has been associated with sulphur-related skin reactions in some patients. Prexige also has a short plasma half-life of approximately four hours, yet provides 24-hour pain relief with a once-daily dose.

The clinical trial database for Prexige comprises approximately 40,000 patients, making it one of the largest bodies of evidence for any drug in its class. This includes the results of TARGET (Therapeutic Arthritis Research and Gastrointestinal Trial) involving more than 18,000 patients[10]. Results of this trial showed Prexige also significantly reduced the incidence of upper gastrointestinal complications by 79% in patients not taking aspirin compared to ibuprofen and naproxen[11].

Novartis supports the recommendation of health authorities that anti-inflammatory treatments should be used in appropriate patients at the lowest possible dose for the shortest possible duration.

Disclaimer The foregoing press release contains forward-looking statements such as "can," "may," or similar expressions, or by express or implied discussions regarding potential future regulatory filings or approvals or potential future sales of Prexige® (lumiracoxib). Such forward-looking statements reflect the current views of Novartis regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Prexige® (lumiracoxib) to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Prexige® (lumiracoxib) will be approved for sale in the U.S. or any other additional markets, or for any additional indicatio
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
(Date:4/17/2014)... Researchers from LSTM have called for more research ... coinfection in children in sub-Saharan Africa. In a ... LSTM,s Professor Russell Stothard, working with colleagues in ... Western Reserve University, in Cleveland Ohio, University of ... previous research into the joint burden of HIV/AIDS ...
(Date:4/16/2014)... , DOWNERS GROVE, Ill. April 16, 2014 ... of surveillance colonoscopy in average-risk patients with one to ... about 90 percent of cases. This may be an ... multicenter endoscopic database study to quantify adherence to guidelines ...
(Date:4/15/2014)... by the RECIST Working Group published in the European ... more refined categorization of tumor response or various aspects of ... database. They found that modeling target lesion tumor growth ... beyond that of the other components of progression. The RECIST ...
(Date:4/14/2014)... USA The International and American Associations for Dental ... Diseases and Their Dental, Oral, and Craniofacial Manifestations." The ... Burke, Alison M. Boyce, Michael Collins, Brian L. Foster, ... Martha J. Somerman and J. Timothy Wright is published ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... from academic and business leaders, technologists, physicians, ... In response to President Obama,s call ... for Connected Health, a division of Partners ... in December, to explore the opportunities and ...
... patients, help rural broadband developmentWASHINGTON, Jan. 22 An ... protect patients from medical errors was adopted by unanimous ... & Commerce Committee,s markup of the Democrats, $825 billion ... secure electronic system to store our medical records, it ...
... 23 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... Sclerosis taking,place this week in Santa Fe, New Mexico. , ... Time: 2:30 - 4:30pm , ... MS , Presentation Title: The orally ...
... DEPTFORD, N.J., Jan. 23 In an effort to ... and Licensed Practical Nurses are set to participate in ... Innova Hammonton scheduled to begin at 6 a.m. on ... The National Union of Hospital and Health Care Employees ...
... open here in March, will provide clients with the opportunity in ... team of expert physicians at a state-of-the-art evaluation facility. , ... ... Health Evaluation Center (WHEC), set to open here in March, will ...
... Stethoscope.com announced today the implementation of customer product reviews for the ... ... Wayland, MA (PRWEB) January 23, 2009 -- Stethoscope.com ... full line of medical products offered on their website., , ,"We ...
Cached Medicine News:Health News:Healthcare Reform Should Include Connected Health and Participatory Medicine, Says Report Submitted to President Obama by Center for Connected Health 2Health News:Healthcare Reform Should Include Connected Health and Participatory Medicine, Says Report Submitted to President Obama by Center for Connected Health 3Health News:New Williamsburg Health Evaluation Center, The Ultimate Investment In Future Health And Well-Being, Set To Open In March 2
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
Medicine Products: